Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis
- PMID: 22241902
- PMCID: PMC3375584
- DOI: 10.1136/annrheumdis-2011-200702
Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis
Abstract
Objectives: To explore the relationship of serious infection risk with current and prior oral glucocorticoid (GC) therapy in elderly patients with rheumatoid arthritis (RA).
Methods: A case-control analysis matched 1947 serious infection cases to five controls, selected from 16207 RA patients aged ≥ 65 between 1985-2003 in Quebec, Canada. Adjusted odds ratios for infection associated with different GC patterns were estimated using conventional models and a weighted cumulative dose (WCD) model.
Results: The WCD model predicted risks better than conventional models. Current and recent GC doses had highest impact on current risk. Doses taken up to 2.5 years ago were also associated with increased risk, albeit to a lesser extent. A current user of 5mg prednisolone had a 30%, 46% or 100% increased risk of serious infection when used continuously for the last 3 months, 6 months or 3 years, respectively, compared to a non-user. The risk associated with 5mg prednisolone taken for the last 3 years was similar to that associated with 30 mg taken for the last month. Discontinuing a two-year course of 10mg prednisolone six months ago halved the risk compared to ongoing use.
Conclusions: GC therapy is associated with infection risk in older patients with RA. The WCD model provided more accurate risk estimates than conventional models. Current and recent doses have greatest impact on infection risk, but the cumulative impact of doses taken in the last 2-3 years still affects risk. Knowing how risk depends on pattern of GC use will contribute to an improved benefit/harm assessment.
Conflict of interest statement
Figures

Similar articles
-
The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study.Ann Rheum Dis. 2011 Jun;70(6):956-60. doi: 10.1136/ard.2010.144741. Epub 2011 Feb 1. Ann Rheum Dis. 2011. PMID: 21285116 Free PMC article.
-
Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis.Rheumatol Int. 2017 Mar;37(3):369-376. doi: 10.1007/s00296-016-3631-z. Epub 2016 Dec 20. Rheumatol Int. 2017. PMID: 27999943 Free PMC article.
-
Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study.Ann Intern Med. 2020 Dec 1;173(11):870-878. doi: 10.7326/M20-1594. Epub 2020 Sep 22. Ann Intern Med. 2020. PMID: 32956604 Free PMC article.
-
[Glucocorticoid-free and low-dose glucocorticoid treatment of rheumatoid arthritis].Z Rheumatol. 2021 May;80(4):305-313. doi: 10.1007/s00393-021-00973-w. Epub 2021 Mar 10. Z Rheumatol. 2021. PMID: 33689031 Review. German.
-
Glucocorticoid treatment in rheumatoid arthritis.Expert Opin Pharmacother. 2014 Aug;15(11):1575-83. doi: 10.1517/14656566.2014.922955. Epub 2014 May 26. Expert Opin Pharmacother. 2014. PMID: 24856989 Review.
Cited by
-
Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study.Clin Rheumatol. 2021 Sep;40(9):3755-3763. doi: 10.1007/s10067-021-05660-4. Epub 2021 Mar 1. Clin Rheumatol. 2021. PMID: 33646447 Free PMC article.
-
Infectious complications in juvenile idiopathic arthritis.Curr Rheumatol Rep. 2013 May;15(5):327. doi: 10.1007/s11926-013-0327-1. Curr Rheumatol Rep. 2013. PMID: 23529583 Review.
-
Respiratory tract infections and risk factors for infection in a cohort of 330 patients with axial spondyloarthritis or psoriatic arthritis.Front Immunol. 2022 Oct 26;13:1040725. doi: 10.3389/fimmu.2022.1040725. eCollection 2022. Front Immunol. 2022. PMID: 36389682 Free PMC article.
-
Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids.Urol Oncol. 2022 Oct;40(10):451.e1-451.e8. doi: 10.1016/j.urolonc.2022.07.015. Epub 2022 Aug 1. Urol Oncol. 2022. PMID: 36008254 Free PMC article.
-
Anncaliia algerae microsporidial myositis.Emerg Infect Dis. 2014 Feb;20(2):185-91. doi: 10.3201/eid2002.131126. Emerg Infect Dis. 2014. PMID: 24447398 Free PMC article.
References
-
- Caplan L, Wolfe F, Russell AS, et al. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007;34:696–705 - PubMed
-
- Thiele K, Buttgereit F, Huscher D, et al. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Rheum 2005;53:740–7 - PubMed
-
- Hoes JN, Jacobs JW, Buttgereit F, et al. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010;6:693–702 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous